Investments in healthcare products and services have expanded in recent years to also focus on new technologies and disruptive innovations, as the combination of the Covid pandemic and increased longevity and ageing populations have caused a shift in this traditionally defensive sector. What does this shift towards biotechnology, breakthrough innovations in life sciences and genomics, remote diagnosis and surgical procedures, to name but a few, mean for the investment case for healthcare?